Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Cefoperazone

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

Cefoperazone (opens in a new tab)Original source URL: https://globalrph.com/dilution/cefoperazone/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/cefoperazone/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:44:45.726151+00:00
Source location
div.post-content
Packaged content SHA-256
6aec246563317b54f25788467a9cc4c945ddb1fea1867c883fcb2b46efd534f0
Original response SHA-256
95d047b62db57aac695578d6a72112ac56ac0925a5866e99d1d35ebd1cf3bac4
Source body SHA-256
a36fa8b16bbd77ab0d8ded9ba7dfd2ac501f457232d53f5cea7777d1c7178698

CEFOPERAZONE (CEFOBID ®)

The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Usual Diluents

D5W, NS

Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate]

[0 to 1 gram] [50 ml] [30 min]
[ Over 1 gram] [100 ml] [30 min]

Stability / Miscellaneous

Label: Refrigerate

DOSAGE AND ADMINISTRATION
The usual adult daily dose of CEFOBID (sterile cefoperazone) is 2 to 4 grams per day administered in equally divided doses every 12 hours.

In severe infections or infections caused by less sensitive organisms, the total daily dose and/or frequency may be increased. Patients have been successfully treated with a total daily dosage of 6-12 grams divided into 2, 3 or 4 administrations ranging from 1.5 to 4 grams per dose.

In a pharmacokinetic study, a total daily dose of 16 grams was administered to severely immunocompromised patients by constant infusion without complications. Steady state serum concentrations were approximately 150 mcg/mL in these patients.

When treating infections caused by Streptococcus pyogenes, therapy should be continued for at least 10 days.

Solutions of CEFOBID and aminoglycoside should not be directly mixed, since there is a physical incompatibility between them. If combination therapy with CEFOBID and an aminoglycoside is contemplated this can be accomplished by sequential intermittent intravenous infusion provided that separate secondary intravenous tubing is used, and that the primary intravenous tubing is adequately irrigated with an approved diluent between doses. It is also suggested that CEFOBID be administered prior to the aminoglycoside. In vitro testing of the effectiveness of drug combination(s) is recommended.

RECONSTITUTION
The following solutions may be used for the initial reconstitution of CEFOBID (sterile cefoperazone). Solutions for Initial Reconstitution (table 1)

5% Dextrose Injection (USP) 0.9% Sodium Chloride Injection (USP)
5% Dextrose and 0.9% Sodium Chloride Injection (USP) Normosol® M and 5% Dextrose Injection
5% Dextrose and 0.2% Sodium Chloride Injection (USP) Normosol® R
10% Dextrose Injection (USP)
Bacteriostatic Water for Injection [Benzyl Alcohol or   Parabens] (USP)* Sterile Water for Injection*
*Not to be used as a vehicle for intravenous infusion.
Preparations containing Benzyl Alcohol should not be used in neonates.

General Reconstitution Procedures
CEFOBID (sterile cefoperazone) for intravenous or intramuscular use may be initially reconstituted with any compatible solution mentioned above in Table 1. Solutions should be allowed to stand after reconstitution to allow any foaming to dissipate to permit visual inspection for complete solubilization. Vigorous and prolonged agitation may be necessary to solubilize CEFOBID in higher concentrations (above 333 mg cefoperazone/mL). The maximum solubility of CEFOBID (sterile cefoperazone) is approximately 475 mg cefoperazone/mL of compatible diluent.

Preparation for Intravenous Use
General

CEFOBID (sterile cefoperazone) concentrations between 2 mg/mL and 50 mg/mL are recommended for intravenous administration.

Preparation of Vials
Vials of CEFOBID (sterile cefoperazone) may be initially reconstituted with a minimum of 2.8 mL per gram of cefoperazone of any compatible reconstituting solution appropriate for intravenous administration listed in the above Table 1. For ease of reconstitution the use of 5 mL of compatible solution per gram of CEFOBID is recommended. The entire quantity of the resulting solution should then be withdrawn for further dilution and administration using any of the following vehicles for intravenous infusion:
Table 2. Vehicles for Intravenous Infusion

5% Dextrose Injection (USP) Lactated Ringer's Injection (USP)
5% Dextrose and Lactated Ringer's Injection 0.9% Sodium Chloride Injection (USP)
5% Dextrose and 0.9% Sodium Chloride Injection (USP) Normosol® M and 5% Dextrose Injection
5% Dextrose and 0.2% Sodium Chloride Injection (USP) Normosol® R
10% Dextrose Injection (USP)

The resulting intravenous solution should be administered in one of the following manners:

Intermittent Infusion
Solutions of CEFOBID should be administered over a 15-30 minute time period.

Continuous Infusion
CEFOBID can be used for continuous infusion after dilution to a final concentration of between 2 and 25 mg cefoperazone per mL.

Preparation for Intramuscular Injection
Any suitable solution listed above may be used to prepare CEFOBID (sterile cefoperazone) for intramuscular injection. When concentrations of 250 mg/mL or more are to be administered, a lidocaine solution should be used. These solutions should be prepared using a combination of Sterile Water for Injection and 2% Lidocaine Hydrochloride Injection (USP) that approximates a 0.5% Lidocaine Hydrochloride Solution. A two-step dilution process as follows is recommended: First, add the required amount of Sterile Water for Injection and agitate until CEFOBID powder is completely dissolved. Second, add the required amount of 2% lidocaine and mix.

Final
Cefoperazone
Concentration
Step 1
Volume of Sterile Water
Step 2
Volume of 2% Lidocaine
Withdrawable Volume*
*There is sufficient excess present to allow for withdrawal of the stated volume.  Final lidocaine concentration will approximate that obtained if a 0.5% Lidocaine Hydrochloride Solution is used as diluent.
1 g vial 333 mg/mL 2.0 mL 0.6 mL 3 mL
250 mg/mL 2.8 mL 1.0 mL 4 mL
2 g vial 333 mg/mL 3.8 mL 1.2 mL 6 mL
250 mg/mL 5.4 mL 1.8 mL 8 mL

When a diluent other than Lidocaine HCl Injection (USP) is used reconstitute as follows:

Cefoperazone Concentration Volume of Diluent to be Added Withdrawable Volume*
*There is sufficient excess present to allow for withdrawal of the stated volume.
1 g vial 333 mg/mL 2.6 mL 3 mL
250 mg/mL 3.8 mL 4 mL
2 g vial 333 mg/mL 5.0 mL 6 mL
250 mg/mL 7.2 mL 8 mL


STORAGE AND STABILITY
CEFOBID (sterile cefoperazone) is to be stored at or below 25°C (77°F) and protected from light prior to reconstitution. After reconstitution, protection from light is not necessary.

The following parenteral diluents and approximate concentrations of CEFOBID provide stable solutions under the following conditions for the indicated time periods. (After the indicated time periods, unused portions of solutions should be discarded.)

Room Temperature (15°–25°C/59°–77°F)
24 Hours Approximate Concentrations
  Bacteriostatic Water for Injection [Benzyl Alcohol or Parabens] (USP) 300 mg/mL
  5% Dextrose Injection (USP) 2 mg to 50 mg/mL
  5% Dextrose and Lactated Ringer's Injection 2 mg to 50 mg/mL
  5% Dextrose and 0.9% Sodium Chloride Injection (USP) 2 mg to 50 mg/mL
  5% Dextrose and 0.2% Sodium Chloride Injection (USP) 2 mg to 50 mg/mL
  10% Dextrose Injection (USP) 2 mg to 50 mg/mL
  Lactated Ringer's Injection (USP) 2 mg/mL
  0.5% Lidocaine Hydrochloride Injection (USP) 300 mg/mL
  0.9% Sodium Chloride Injection (USP) 2 mg to 300 mg/mL
  Normosol® M and 5% Dextrose Injection 2 mg to 50 mg/mL
  Normosol® R 2 mg to 50 mg/mL
  Sterile Water for Injection 300 mg/mL
  Reconstituted CEFOBID solutions may be stored in glass or plastic syringes, or in glass or flexible plastic parenteral solution containers.
Refrigerator Temperature (2°–8°C/36°–46°F)
5 Days Approximate Concentrations
  Bacteriostatic Water for Injection [Benzyl Alcohol or Parabens] (USP) 300 mg/mL
  5% Dextrose Injection (USP) 2 mg to 50 mg/mL
  5% Dextrose and 0.9% Sodium Chloride Injection (USP) 2 mg to 50 mg/mL
  5% Dextrose and 0.2% Sodium Chloride Injection (USP) 2 mg to 50 mg/mL
  Lactated Ringer's Injection (USP) 2 mg/mL
  0.5% Lidocaine Hydrochloride Injection (USP) 300 mg/mL
  0.9% Sodium Chloride Injection (USP) 2 mg to 300 mg/mL
  Normosol® M and 5% Dextrose Injection 2 mg to 50 mg/mL
  Normosol® R 2 mg to 50 mg/mL
  Sterile Water for Injection 300 mg/mL
  Reconstituted CEFOBID solutions may be stored in glass or plastic syringes, or in glass or   flexible plastic parenteral solution containers.
Freezer Temperature –20° to –10°C/–4°to 14°F)
3 Weeks Approximate Concentrations
  5% Dextrose Injection (USP) 50 mg/mL
  5% Dextrose and 0.9% Sodium Chloride Injection (USP) 2 mg/mL
  5% Dextrose and 0.2% Sodium Chloride Injection (USP) 2 mg/mL
5 Weeks
  0.9% Sodium Chloride Injection (USP) 300 mg/mL
  Sterile Water for Injection 300 mg/mL
  Reconstituted CEFOBID solutions may be stored in plastic syringes, or in flexible plastic parenteral solution containers.

Frozen samples should be thawed at room temperature before use. After thawing, unused portions should be discarded. Do not refreeze.

HOW SUPPLIED
CEFOBID (sterile cefoperazone) is available in vials containing cefoperazone sodium equivalent to 1 g cefoperazone × 10 (NDC 0049-1201-83) and 2 g cefoperazone × 10 (NDC 0049-1202-83) for intramuscular and intravenous administration.

CEFOBID (sterile cefoperazone) is available in 10 g (NDC 0049-1219-28) Pharmacy Bulk Package for intravenous administration.

Open this historical article on its own

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
adjustment_required
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        class_level
        Provenance classification
        historical_class_level
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      cefoperazone
      Source IDH51-9E892A51E32BADA3CEB3FCAF
      Generic name
      Cefoperazone
      Source IDH51-BFC631F1EB1AD46785C65C8E
      Class
      Antibacterial
      Source IDH51-E9EBE2727BB8727622EBD0F1
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-60C624734CE161077D01AF0F
      Primary uses
      1. Selected susceptible bacterial infections; indication, site, organism, local susceptibility, and current labeling determine use.
        Source IDH51-8A9F5D7C0A49C66DA46AE1C3
      Mechanism
      Beta-lactam binding to bacterial penicillin-binding proteins inhibits peptidoglycan cross-linking and cell-wall synthesis.
      Source IDH51-FCAB311BB9E45BFE6440226D
      Mechanism level
      class_level
      Source IDH51-66F3AFA25CCB55BBC16E2DC1
      Basic dosing orientation
      The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy.
      Source IDH51-043B09AEAF9098714A5730C6
      Administration orientation
      Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required.
      Source IDH51-AACC59E1EC7F7A3705288DCC
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal dose adjustment or interval modification is commonly required; verify the selected product label and patient-specific renal method.
      Source IDH51-282A6FD5DD4AB213A02102FC
      Key safety orientation
      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-E777B213F00BBCA5D55D2F47
      Coverage path
      automatic_legacy_quick_reference
      Source IDH51-23D23E40357C57AF23075BDF
      Coverage path label
      Automatic legacy GlobalRPh quick reference
      Source IDH51-0A07427BCABD28535E2A54C3
      Legacy title
      Cefoperazone
      Source IDH51-8E429001012B34CFE4C2AB1C
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-0B0D1ECF2680E7E2B3BADE21
      Search text
      Cefoperazone Antibacterial Legacy GlobalRPh directory entry Selected susceptible bacterial infections; indication, site, organism, local susceptibility, and current labeling determine use. Beta-lactam binding to bacterial penicillin-binding proteins inhibits peptidoglycan cross-linking and cell-wall synthesis. The existing GlobalRPh dose and preparation quick reference loads automatically below. Treat it as historical continuity, then confirm the exact current DailyMed label, population, indication, renal function, and institutional policy. Route, dilution, concentration, and administration details load automatically from the existing GlobalRPh quick reference below; current exact-product verification remains required. Renal dose adjustment or interval modification is commonly required; verify the selected product label and patient-specific renal method. Legacy content must be reconciled against current labeling and institutional policy before clinical use. Automatic legacy GlobalRPh quick reference
      Source IDH51-53CDEA92DFC8FC09679398AF
      Official access mode
      search
      Source IDH51-06E485F3F9C114B6386E00ED
      Official search query
      Cefoperazone
      Source IDH51-E3828A5525A828589C483B6B
      Official access reason
      A source-backed DailyMed search is available; select and confirm the exact IV product.
      Source IDH51-89287216679984A859D966FF

      No separate structured rows were bundled for preparation, IV push, continuous infusion, population dosing, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      adjustment_required
      Source IDH51-35697882FCB1E5E226BB3905
      Summary
      Renal dose adjustment or interval modification is commonly required; verify the selected product label and patient-specific renal method.
      Source IDH51-8E8C2E97453E3B497125129E
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-86005C42D114268FFA942247

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy content must be reconciled against current labeling and institutional policy before clinical use.
        Source IDH51-53E0A3EF130A0B524285192A

      Historical Stability notes

      Recovered v5.1 source content; historical, awaiting current review.

      1. Legacy product stability information is not automatically equivalent to a USP <797> BUD.
        Source IDH51-617EF15A888D8C82FEE2A050

      Historical supplemental professional sources

      Recovered v5.1 source content; historical, awaiting current review.

      LabelUrlKind
      Source IDH51-56809FBCFBBDF0AF4CC2869D
      UCSF adult antimicrobial dosing, non-dialysis
      Source IDH51-A5099074DCCACF34351E482D
      https://idmp.ucsf.edu/adult-antimicrobial-dosing-non-dialysis (opens in a new tab)
      Source IDH51-89BB2C6B5B75C7A0A16D0138
      Professional institutional guidance
      Source IDH51-7E05FAFCF78A6AE754B41392
      Source IDH51-A179FA88DF39A651DB8E994F
      UCSF antimicrobial dosing in intermittent and continuous hemodialysis
      Source IDH51-BA5DBF15C6372C31A8850604
      https://idmp.ucsf.edu/antimicrobial-dosing-intermittent-continuous-hemodialysis (opens in a new tab)
      Source IDH51-27E30D351A4E519C48C70F1F
      Professional institutional guidance
      Source IDH51-466D3AEE0E9640F3ACF723C5
      Source IDH51-1A1D5B8D6A1706DB319539C4
      UCSF pediatric antimicrobial dosing
      Source IDH51-DA8748C9653B1362A521F9D5
      https://idmp.ucsf.edu/pediatric-antimicrobial-dosing-benioff-childrens-hospitals (opens in a new tab)
      Source IDH51-415C20783AC1A2F16E1141FC
      Professional institutional guidance
      Source IDH51-B3BB19EEE8DE6AF2928C1520
      Source IDH51-504137E8834F8F8C586C39F0
      UCSF neonatal antimicrobial dosing
      Source IDH51-D0942039BCD074A1D75DA6BE
      https://idmp.ucsf.edu/neonatal-antimicrobial-dosing-benioff-childrens-hospitals (opens in a new tab)
      Source IDH51-15EF97B6B5BA2EC136E80E6A
      Professional institutional guidance
      Source IDH51-1DEDB0785D9791ADE660914C
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      cefoperazone
      Source IDH51-9A191C4AE039D699340E7E2D
      Legacy title
      Cefoperazone
      Source IDH51-4D0C43A574D05E609BA80BA2
      Generic name
      Cefoperazone
      Source IDH51-CE5B49D5FF5A574D5614F675
      Class
      Antibacterial
      Source IDH51-2B35A0FDFDCD005E227A4AF2
      Subclass
      Legacy GlobalRPh directory entry
      Source IDH51-5C46003AA47C3776825F65C0
      Summary
      Existing GlobalRPh IV dilution monograph retained for migration into the unified reference.
      Source IDH51-06806264A3D86AA642D0367B
      Populations
      1. Population not yet normalized
        Source IDH51-7FB56FBE1D64F1B14DA4D459
      Evidence tier
      Legacy catalog - migration review required
      Source IDH51-CE0FD231C27D1DD1970F17A6
      High alert
      false
      Source IDH51-91E5DBEE8F2E853E52468720
      Hazardous
      false
      Source IDH51-0B5BD312788D2592D5E3ECBA
      Status
      Legacy migration
      Source IDH51-D95D70C420B4A5169FDE9D53
      Version added
      Legacy
      Source IDH51-80A80B7C0E8D3F48E6453993
      Sources
      LabelUrlKind
      Source IDH51-7624543D1C9DA5FFD5806CE1
      GlobalRPh legacy IV dilution monograph
      Source IDH51-C5D35C3151A7A6242D78640F
      legacy:auto
      Source IDH51-18976085689802E26D61D506
      Legacy
      Source IDH51-C0E6F151EBC4C87444CC1872
      Clinical release verification
      Audit version
      3.4
      Source IDH51-11E2BDEBD00FEF60C35B2D9F
      Audited on
      2026-08-30
      Source IDH51-E1BA90DF362CCA57CA960F7D
      Level
      amber
      Source IDH51-6F67A3A4B5BFC8F0545987F9
      Release gate
      trusted_professional_source_present_exact_label_unconfirmed
      Source IDH51-91BF9F17D88BCA37F0664AE5
      Exact current label candidate
      false
      Source IDH51-370373989F024AC65E640E8C
      Reference url count
      4
      Source IDH51-6D9E6F112DED9F934DFCEAD4
      Broken reference count
      0
      Source IDH51-16DA8D96FFC7B94A52E899D5
      Point of use confirmation required
      true
      Source IDH51-F223CD28A4D1F64229E261CA
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-8868459E003858253FB614D6

      Dosing source fields

      Id
      cefoperazone
      Source IDH51-BAC36B857D6DE1211C3D6FF9
      Generic name
      Cefoperazone
      Source IDH51-D99AC75A0AE712B5C53F204D
      Coverage status
      direct_official_label_access_plus_legacy_reference
      Source IDH51-6B8B1C821E40BAB9C7B14A19
      Package insert
      Query name
      Cefoperazone
      Source IDH51-322333676709BA7CC0FB0B90
      Product and route must match
      true
      Source IDH51-6F92D3A6668353BF16767AAF
      Live current label enabled
      false
      Source IDH51-778A1293E57FE7245F8B9357
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-537B4D039F0F54C9A0AD75DC
      Direct official label access enabled
      true
      Source IDH51-AEAFBAF798739EAEC49873DC
      Outbound server request required
      false
      Source IDH51-3E4C972CAFCC235A026AF619
      Local summary status
      not_bundled
      Source IDH51-6358E233DB8C4ED1123AC8E7
      Clinical review
      Locally normalized
      false
      Source IDH51-A9771F7D630138233BCE3582
      Reviewed
      2026-08-29
      Source IDH51-D3DD4557A1937DB2912BD237
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-AF665322B9F591F0BE49BA09
      Clinical release verification
      Audit version
      3.4
      Source IDH51-350C731EB9D1522E5AA06311
      Audited on
      2026-08-30
      Source IDH51-4AEB6E7A43E324F470F71213
      Level
      amber
      Source IDH51-6DD22D99DCFE6D432FFADD2E
      Release gate
      trusted_professional_source_present_exact_label_unconfirmed
      Source IDH51-2BA36209E1E7AE79E817490C
      Exact current label candidate
      false
      Source IDH51-FC65B37B1C3C775F124BB1A1
      Reference url count
      4
      Source IDH51-D1BD04873405749BC9296627
      Broken reference count
      0
      Source IDH51-4F18898DE542ACA695B0CA22
      Point of use confirmation required
      true
      Source IDH51-FC32BAD8D2F693A46E028B10
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-CD2B0B2F0DDBBECAA9044D9B
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      cefoperazone
      Source IDH51-33241A167360DF1DD4AF29B4
      Name
      Cefoperazone
      Source IDH51-A86DEE3C339CEBF86BE4820A
      Therapeutic class
      Antibacterial
      Source IDH51-BD0D7B4DBE9FE6CCA2C62CC5
      Review version
      3.1
      Source IDH51-B87A4D7ED96B46B4D48850E3
      Review date
      2026-08-30
      Source IDH51-3D2426361672921EA380301F
      Release status
      no_released_dilution_current_label_review_required
      Source IDH51-7361AB3A72F1DD6A7AF5B3C5
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-19C8B83376E46450B23AA160
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-387DBF9969A546999CC59312
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-D4382790619254F8079E45B2
      Reconstitution concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-75B69208C1E244199270D6C2
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-1A1AF6E8882AD615293D8751
      Appropriate standardized containers
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-E0A2289CDB10D9F10478D29E
      Adult dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-41F5DDA69DB0651AD7452D3D
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-277BD0D1E64D3B76371D8559
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-7D91200639E60E127AFE8857
      Infusion time
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-34C776F88B2A75590434FBF6
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-4F396C1224DDBC2253251914
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-5BD7D55139B4B2104C954406
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-83A15495C3B2A1EC1C07B6CB
      Reconstitution concentration
      Primary
      not_found
      Source IDH51-5BD42F13D9F385658D969609
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-9E5B9CBF58444644FE31A924
      Appropriate standardized containers
      Primary
      not_found
      Source IDH51-2DA2892474D9AE6CAA068FD6
      Adult dosing range
      Primary
      not_found
      Source IDH51-86664933C412FF0F938EFA07
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-4A5CD974AD618BCAFE403170
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-AA1322D0170A02D19D908ABD
      Infusion time
      Primary
      not_found
      Source IDH51-903B6A01837D631D61FBD9E5
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-824681CC19C13E52B0575A40
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-CF69FB3A703FD5DA64127C71
      Population applicability
      Adult
      Applicability
      not_established
      Source IDH51-785243264D2D38C7A5FC00D0
      Guide generation allowed
      false
      Source IDH51-F1D9A85E806F22779373AAB4
      Pediatric
      Applicability
      supported_or_source_present
      Source IDH51-815851DAFCAFFBB7E2B28343
      Guide generation allowed
      false
      Source IDH51-DE67A9A39DCDDF7FCE7727C4
      Neonatal
      Applicability
      supported_or_source_present
      Source IDH51-A754EC262DEB35A7FF0973CA
      Guide generation allowed
      false
      Source IDH51-1CE2D0F8ADDB529AF2AA6719
      Route presence
      Structured dilution
      false
      Source IDH51-6F6CAB6233EF4DAADD52F7A7
      Iv push
      false
      Source IDH51-B709E3C8FA7A37067515A624
      Continuous infusion
      false
      Source IDH51-FBD617B100FD8D9BB6C37F94
      Pediatric source
      true
      Source IDH51-95FB06DCF82ED9DCD7393D59
      Neonatal source
      true
      Source IDH51-8871A054EAE04A0B6DE567BE
      Legacy reference
      Status
      not_available
      Source IDH51-8C2D08461384224C22F7EE25
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-032CF24C1546673FF5E45830
      Source files
      1. catalog.json
        Source IDH51-C62A77125C4CAC9C9BC85F6E
      2. dosing.json
        Source IDH51-A8A879C59DA7AB94788F1B37
      3. legacy-map.json
        Source IDH51-678C3AF08AD2B4F8C6A6097E
      4. review-queue.json
        Source IDH51-514EE5AF2EC5EE4105F6271C
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-122D69CE72DD6432746EB94A
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-9A191C4AE039D699340E7E2Dcatalog.json
      /records/47/id
      Historical; current review incomplete
      H51-4D0C43A574D05E609BA80BA2catalog.json
      /records/47/legacy_title
      Historical; current review incomplete
      H51-CE5B49D5FF5A574D5614F675catalog.json
      /records/47/generic_name
      Historical; current review incomplete
      H51-2B35A0FDFDCD005E227A4AF2catalog.json
      /records/47/class
      Historical; current review incomplete
      H51-5C46003AA47C3776825F65C0catalog.json
      /records/47/subclass
      Historical; current review incomplete
      H51-06806264A3D86AA642D0367Bcatalog.json
      /records/47/summary
      Historical; current review incomplete
      H51-53E0A3EF130A0B524285192Acatalog.json
      /records/47/warnings/0
      Historical; current review incomplete
      H51-617EF15A888D8C82FEE2A050catalog.json
      /records/47/stability_notes/0
      Historical; current review incomplete
      H51-7FB56FBE1D64F1B14DA4D459catalog.json
      /records/47/populations/0
      Historical; current review incomplete
      H51-CE0FD231C27D1DD1970F17A6catalog.json
      /records/47/evidence_tier
      Historical; current review incomplete
      H51-91E5DBEE8F2E853E52468720catalog.json
      /records/47/high_alert
      Historical; current review incomplete
      H51-0B5BD312788D2592D5E3ECBAcatalog.json
      /records/47/hazardous
      Historical; current review incomplete
      H51-D95D70C420B4A5169FDE9D53catalog.json
      /records/47/status
      Historical; current review incomplete
      H51-91381D4C5CC18EBA0B92B348catalog.json
      /records/47/reviewed
      Historical; current review incomplete
      H51-80A80B7C0E8D3F48E6453993catalog.json
      /records/47/version_added
      Historical; current review incomplete
      H51-7624543D1C9DA5FFD5806CE1catalog.json
      /records/47/sources/0
      Historical; current review incomplete
      H51-C5D35C3151A7A6242D78640Fcatalog.json
      /records/47/sources/0/label
      Historical; current review incomplete
      H51-18976085689802E26D61D506catalog.json
      /records/47/sources/0/url
      Historical; current review incomplete
      H51-C0E6F151EBC4C87444CC1872catalog.json
      /records/47/sources/0/kind
      Historical; current review incomplete
      H51-11E2BDEBD00FEF60C35B2D9Fcatalog.json
      /records/47/clinical_release_verification/audit_version
      Historical; current review incomplete
      H51-E1BA90DF362CCA57CA960F7Dcatalog.json
      /records/47/clinical_release_verification/audited_on
      Historical; current review incomplete
      H51-6F67A3A4B5BFC8F0545987F9catalog.json
      /records/47/clinical_release_verification/level
      Historical; current review incomplete
      H51-91BF9F17D88BCA37F0664AE5catalog.json
      /records/47/clinical_release_verification/release_gate
      Historical; current review incomplete
      H51-370373989F024AC65E640E8Ccatalog.json
      /records/47/clinical_release_verification/exact_current_label_candidate
      Historical; current review incomplete
      H51-EEDA68781B9637801D07309Bcatalog.json
      /records/47/clinical_release_verification/selected_setid
      Historical; current review incomplete
      H51-5EA0A8B8D466286D2A5AA581catalog.json
      /records/47/clinical_release_verification/selected_label_title
      Historical; current review incomplete
      H51-F240345917C310E47588C7B6catalog.json
      /records/47/clinical_release_verification/numeric_support_ratio
      Historical; current review incomplete
      H51-6D9E6F112DED9F934DFCEAD4catalog.json
      /records/47/clinical_release_verification/reference_url_count
      Historical; current review incomplete
      H51-16DA8D96FFC7B94A52E899D5catalog.json
      /records/47/clinical_release_verification/broken_reference_count
      Historical; current review incomplete
      H51-F223CD28A4D1F64229E261CAcatalog.json
      /records/47/clinical_release_verification/point_of_use_confirmation_required
      Historical; current review incomplete
      H51-8868459E003858253FB614D6catalog.json
      /records/47/clinical_release_verification/note
      Historical; current review incomplete
      H51-81AD9BD4315ABB3133F6A344catalog.json
      /records/47/clinical_release_verification/dailymed_search_url
      Historical; current review incomplete
      H51-BAC36B857D6DE1211C3D6FF9dosing.json
      /records/47/id
      Historical; current review incomplete
      H51-D99AC75A0AE712B5C53F204Ddosing.json
      /records/47/generic_name
      Historical; current review incomplete
      H51-6B8B1C821E40BAB9C7B14A19dosing.json
      /records/47/coverage_status
      Historical; current review incomplete
      H51-322333676709BA7CC0FB0B90dosing.json
      /records/47/package_insert/query_name
      Historical; current review incomplete
      H51-FA6134954C01FEBC122A584Fdosing.json
      /records/47/package_insert/preferred_setid
      Historical; current review incomplete
      H51-6F92D3A6668353BF16767AAFdosing.json
      /records/47/package_insert/product_and_route_must_match
      Historical; current review incomplete
      H51-778A1293E57FE7245F8B9357dosing.json
      /records/47/package_insert/live_current_label_enabled
      Historical; current review incomplete
      H51-537B4D039F0F54C9A0AD75DCdosing.json
      /records/47/package_insert/source_priority
      Historical; current review incomplete
      H51-AEAFBAF798739EAEC49873DCdosing.json
      /records/47/package_insert/direct_official_label_access_enabled
      Historical; current review incomplete
      H51-3E4C972CAFCC235A026AF619dosing.json
      /records/47/package_insert/outbound_server_request_required
      Historical; current review incomplete
      H51-6358E233DB8C4ED1123AC8E7dosing.json
      /records/47/package_insert/local_summary_status
      Historical; current review incomplete
      H51-35697882FCB1E5E226BB3905dosing.json
      /records/47/renal/classification
      Historical; current review incomplete
      H51-8E8C2E97453E3B497125129Edosing.json
      /records/47/renal/summary
      Historical; current review incomplete
      H51-86005C42D114268FFA942247dosing.json
      /records/47/renal/method_note
      Historical; current review incomplete
      H51-56809FBCFBBDF0AF4CC2869Ddosing.json
      /records/47/professional_sources/0
      Historical; current review incomplete
      H51-A5099074DCCACF34351E482Ddosing.json
      /records/47/professional_sources/0/label
      Historical; current review incomplete
      H51-89BB2C6B5B75C7A0A16D0138dosing.json
      /records/47/professional_sources/0/url
      Historical; current review incomplete
      H51-7E05FAFCF78A6AE754B41392dosing.json
      /records/47/professional_sources/0/kind
      Historical; current review incomplete
      H51-A179FA88DF39A651DB8E994Fdosing.json
      /records/47/professional_sources/1
      Historical; current review incomplete
      H51-BA5DBF15C6372C31A8850604dosing.json
      /records/47/professional_sources/1/label
      Historical; current review incomplete
      H51-27E30D351A4E519C48C70F1Fdosing.json
      /records/47/professional_sources/1/url
      Historical; current review incomplete
      H51-466D3AEE0E9640F3ACF723C5dosing.json
      /records/47/professional_sources/1/kind
      Historical; current review incomplete
      H51-1A1D5B8D6A1706DB319539C4dosing.json
      /records/47/professional_sources/2
      Historical; current review incomplete
      H51-DA8748C9653B1362A521F9D5dosing.json
      /records/47/professional_sources/2/label
      Historical; current review incomplete
      H51-415C20783AC1A2F16E1141FCdosing.json
      /records/47/professional_sources/2/url
      Historical; current review incomplete
      H51-B3BB19EEE8DE6AF2928C1520dosing.json
      /records/47/professional_sources/2/kind
      Historical; current review incomplete
      H51-504137E8834F8F8C586C39F0dosing.json
      /records/47/professional_sources/3
      Historical; current review incomplete
      H51-D0942039BCD074A1D75DA6BEdosing.json
      /records/47/professional_sources/3/label
      Historical; current review incomplete
      H51-15EF97B6B5BA2EC136E80E6Adosing.json
      /records/47/professional_sources/3/url
      Historical; current review incomplete
      H51-1DEDB0785D9791ADE660914Cdosing.json
      /records/47/professional_sources/3/kind
      Historical; current review incomplete
      H51-A9771F7D630138233BCE3582dosing.json
      /records/47/clinical_review/locally_normalized
      Historical; current review incomplete
      H51-D3DD4557A1937DB2912BD237dosing.json
      /records/47/clinical_review/reviewed
      Historical; current review incomplete
      H51-AF665322B9F591F0BE49BA09dosing.json
      /records/47/clinical_review/status
      Historical; current review incomplete
      H51-350C731EB9D1522E5AA06311dosing.json
      /records/47/clinical_release_verification/audit_version
      Historical; current review incomplete
      H51-4AEB6E7A43E324F470F71213dosing.json
      /records/47/clinical_release_verification/audited_on
      Historical; current review incomplete
      H51-6DD22D99DCFE6D432FFADD2Edosing.json
      /records/47/clinical_release_verification/level
      Historical; current review incomplete
      H51-2BA36209E1E7AE79E817490Cdosing.json
      /records/47/clinical_release_verification/release_gate
      Historical; current review incomplete
      H51-FC65B37B1C3C775F124BB1A1dosing.json
      /records/47/clinical_release_verification/exact_current_label_candidate
      Historical; current review incomplete
      H51-6548C236087E2101411797ECdosing.json
      /records/47/clinical_release_verification/selected_setid
      Historical; current review incomplete
      H51-DB6E34652C6A1E9DE2906335dosing.json
      /records/47/clinical_release_verification/selected_label_title
      Historical; current review incomplete
      H51-0B703654975DC103C59233F0dosing.json
      /records/47/clinical_release_verification/numeric_support_ratio
      Historical; current review incomplete
      H51-D1BD04873405749BC9296627dosing.json
      /records/47/clinical_release_verification/reference_url_count
      Historical; current review incomplete
      H51-4F18898DE542ACA695B0CA22dosing.json
      /records/47/clinical_release_verification/broken_reference_count
      Historical; current review incomplete
      H51-FC32BAD8D2F693A46E028B10dosing.json
      /records/47/clinical_release_verification/point_of_use_confirmation_required
      Historical; current review incomplete
      H51-CD2B0B2F0DDBBECAA9044D9Bdosing.json
      /records/47/clinical_release_verification/note
      Historical; current review incomplete
      H51-E12F9C1EC2B876E8C883D83Adosing.json
      /records/47/clinical_release_verification/dailymed_search_url
      Historical; current review incomplete
      H51-9E892A51E32BADA3CEB3FCAFfirst-look-v5.1.json
      /records/47/id
      Historical; current review incomplete
      H51-BFC631F1EB1AD46785C65C8Efirst-look-v5.1.json
      /records/47/generic_name
      Historical; current review incomplete
      H51-E9EBE2727BB8727622EBD0F1first-look-v5.1.json
      /records/47/class
      Historical; current review incomplete
      H51-60C624734CE161077D01AF0Ffirst-look-v5.1.json
      /records/47/subclass
      Historical; current review incomplete
      H51-8A9F5D7C0A49C66DA46AE1C3first-look-v5.1.json
      /records/47/primary_uses/0
      Historical; current review incomplete
      H51-FCAB311BB9E45BFE6440226Dfirst-look-v5.1.json
      /records/47/mechanism
      Historical; current review incomplete
      H51-66F3AFA25CCB55BBC16E2DC1first-look-v5.1.json
      /records/47/mechanism_level
      Historical; current review incomplete
      H51-043B09AEAF9098714A5730C6first-look-v5.1.json
      /records/47/basic_dosing_orientation
      Historical; current review incomplete
      H51-AACC59E1EC7F7A3705288DCCfirst-look-v5.1.json
      /records/47/administration_orientation
      Historical; current review incomplete
      H51-282A6FD5DD4AB213A02102FCfirst-look-v5.1.json
      /records/47/renal_and_population_orientation
      Historical; current review incomplete
      H51-E777B213F00BBCA5D55D2F47first-look-v5.1.json
      /records/47/key_safety_orientation/0
      Historical; current review incomplete
      H51-23D23E40357C57AF23075BDFfirst-look-v5.1.json
      /records/47/coverage_path
      Historical; current review incomplete
      H51-0A07427BCABD28535E2A54C3first-look-v5.1.json
      /records/47/coverage_path_label
      Historical; current review incomplete
      H51-E4E3B57FC29C2B586B48BE71first-look-v5.1.json
      /records/47/official_label_url
      Historical; current review incomplete
      H51-8E429001012B34CFE4C2AB1Cfirst-look-v5.1.json
      /records/47/legacy_title
      Historical; current review incomplete
      H51-0B0D1ECF2680E7E2B3BADE21first-look-v5.1.json
      /records/47/review_note
      Historical; current review incomplete
      H51-53CDEA92DFC8FC09679398AFfirst-look-v5.1.json
      /records/47/search_text
      Historical; current review incomplete
      H51-AD622088B4576EC15EBAAA23first-look-v5.1.json
      /records/47/official_search_url
      Historical; current review incomplete
      H51-06E485F3F9C114B6386E00EDfirst-look-v5.1.json
      /records/47/official_access_mode
      Historical; current review incomplete
      H51-DD6D0DECCCFA555F072FC4A9first-look-v5.1.json
      /records/47/official_access_url
      Historical; current review incomplete
      H51-E3828A5525A828589C483B6Bfirst-look-v5.1.json
      /records/47/official_search_query
      Historical; current review incomplete
      H51-89287216679984A859D966FFfirst-look-v5.1.json
      /records/47/official_access_reason
      Historical; current review incomplete
      H51-33241A167360DF1DD4AF29B4preparation-assessments-v3.8.json
      /47/id
      Historical; current review incomplete
      H51-A86DEE3C339CEBF86BE4820Apreparation-assessments-v3.8.json
      /47/name
      Historical; current review incomplete
      H51-71A506B392154A3F756B8EF1preparation-assessments-v3.8.json
      /47/brands
      Historical; current review incomplete
      H51-BD0D7B4DBE9FE6CCA2C62CC5preparation-assessments-v3.8.json
      /47/therapeutic_class
      Historical; current review incomplete
      H51-B87A4D7ED96B46B4D48850E3preparation-assessments-v3.8.json
      /47/review_version
      Historical; current review incomplete
      H51-3D2426361672921EA380301Fpreparation-assessments-v3.8.json
      /47/review_date
      Historical; current review incomplete
      H51-7361AB3A72F1DD6A7AF5B3C5preparation-assessments-v3.8.json
      /47/release_status
      Historical; current review incomplete
      H51-19C8B83376E46450B23AA160preparation-assessments-v3.8.json
      /47/market_status/status
      Historical; current review incomplete
      H51-387DBF9969A546999CC59312preparation-assessments-v3.8.json
      /47/market_status/basis
      Historical; current review incomplete
      H51-D4382790619254F8079E45B2preparation-assessments-v3.8.json
      /47/ten_point_assessment/exact_formulation
      Historical; current review incomplete
      H51-75B69208C1E244199270D6C2preparation-assessments-v3.8.json
      /47/ten_point_assessment/reconstitution_concentration
      Historical; current review incomplete
      H51-1A1AF6E8882AD615293D8751preparation-assessments-v3.8.json
      /47/ten_point_assessment/maximum_or_recommended_final_concentration
      Historical; current review incomplete
      H51-E0A2289CDB10D9F10478D29Epreparation-assessments-v3.8.json
      /47/ten_point_assessment/appropriate_standardized_containers
      Historical; current review incomplete
      H51-41F5DDA69DB0651AD7452D3Dpreparation-assessments-v3.8.json
      /47/ten_point_assessment/adult_dosing_range
      Historical; current review incomplete
      H51-277BD0D1E64D3B76371D8559preparation-assessments-v3.8.json
      /47/ten_point_assessment/pediatric_dosing_range
      Historical; current review incomplete
      H51-7D91200639E60E127AFE8857preparation-assessments-v3.8.json
      /47/ten_point_assessment/neonatal_dosing_range
      Historical; current review incomplete
      H51-34C776F88B2A75590434FBF6preparation-assessments-v3.8.json
      /47/ten_point_assessment/infusion_time
      Historical; current review incomplete
      H51-4F396C1224DDBC2253251914preparation-assessments-v3.8.json
      /47/ten_point_assessment/fluid_restriction_alternatives
      Historical; current review incomplete
      H51-25D0CA58F2313E2F85C69148preparation-assessments-v3.8.json
      /47/ten_point_assessment/current_manufacturer_labeling/setid
      Historical; current review incomplete
      H51-3600A994F4F8C2FD529F9960preparation-assessments-v3.8.json
      /47/ten_point_assessment/current_manufacturer_labeling/title
      Historical; current review incomplete
      H51-9DE670E50EEB37F4D83C42E8preparation-assessments-v3.8.json
      /47/ten_point_assessment/current_manufacturer_labeling/published_date
      Historical; current review incomplete
      H51-606A21235D23A5CDDB767776preparation-assessments-v3.8.json
      /47/ten_point_assessment/current_manufacturer_labeling/manufacturer
      Historical; current review incomplete
      H51-5BD7D55139B4B2104C954406preparation-assessments-v3.8.json
      /47/ten_point_assessment/current_manufacturer_labeling/match_confidence
      Historical; current review incomplete
      H51-3E9196BD0F4A42210402A944preparation-assessments-v3.8.json
      /47/ten_point_assessment/current_manufacturer_labeling/url
      Historical; current review incomplete
      H51-83A15495C3B2A1EC1C07B6CBpreparation-assessments-v3.8.json
      /47/field_provenance/exact_formulation/primary
      Historical; current review incomplete
      H51-5BD42F13D9F385658D969609preparation-assessments-v3.8.json
      /47/field_provenance/reconstitution_concentration/primary
      Historical; current review incomplete
      H51-9E5B9CBF58444644FE31A924preparation-assessments-v3.8.json
      /47/field_provenance/maximum_or_recommended_final_concentration/primary
      Historical; current review incomplete
      H51-2DA2892474D9AE6CAA068FD6preparation-assessments-v3.8.json
      /47/field_provenance/appropriate_standardized_containers/primary
      Historical; current review incomplete
      H51-86664933C412FF0F938EFA07preparation-assessments-v3.8.json
      /47/field_provenance/adult_dosing_range/primary
      Historical; current review incomplete
      H51-4A5CD974AD618BCAFE403170preparation-assessments-v3.8.json
      /47/field_provenance/pediatric_dosing_range/primary
      Historical; current review incomplete
      H51-AA1322D0170A02D19D908ABDpreparation-assessments-v3.8.json
      /47/field_provenance/neonatal_dosing_range/primary
      Historical; current review incomplete
      H51-903B6A01837D631D61FBD9E5preparation-assessments-v3.8.json
      /47/field_provenance/infusion_time/primary
      Historical; current review incomplete
      H51-824681CC19C13E52B0575A40preparation-assessments-v3.8.json
      /47/field_provenance/fluid_restriction_alternatives/primary
      Historical; current review incomplete
      H51-CF69FB3A703FD5DA64127C71preparation-assessments-v3.8.json
      /47/field_provenance/current_manufacturer_labeling/primary
      Historical; current review incomplete
      H51-785243264D2D38C7A5FC00D0preparation-assessments-v3.8.json
      /47/population_applicability/adult/applicability
      Historical; current review incomplete
      H51-F1D9A85E806F22779373AAB4preparation-assessments-v3.8.json
      /47/population_applicability/adult/guide_generation_allowed
      Historical; current review incomplete
      H51-815851DAFCAFFBB7E2B28343preparation-assessments-v3.8.json
      /47/population_applicability/pediatric/applicability
      Historical; current review incomplete
      H51-DE67A9A39DCDDF7FCE7727C4preparation-assessments-v3.8.json
      /47/population_applicability/pediatric/guide_generation_allowed
      Historical; current review incomplete
      H51-A754EC262DEB35A7FF0973CApreparation-assessments-v3.8.json
      /47/population_applicability/neonatal/applicability
      Historical; current review incomplete
      H51-1CE2D0F8ADDB529AF2AA6719preparation-assessments-v3.8.json
      /47/population_applicability/neonatal/guide_generation_allowed
      Historical; current review incomplete
      H51-6F6CAB6233EF4DAADD52F7A7preparation-assessments-v3.8.json
      /47/route_presence/structured_dilution
      Historical; current review incomplete
      H51-B709E3C8FA7A37067515A624preparation-assessments-v3.8.json
      /47/route_presence/iv_push
      Historical; current review incomplete
      H51-FBD617B100FD8D9BB6C37F94preparation-assessments-v3.8.json
      /47/route_presence/continuous_infusion
      Historical; current review incomplete
      H51-95FB06DCF82ED9DCD7393D59preparation-assessments-v3.8.json
      /47/route_presence/pediatric_source
      Historical; current review incomplete
      H51-8871A054EAE04A0B6DE567BEpreparation-assessments-v3.8.json
      /47/route_presence/neonatal_source
      Historical; current review incomplete
      H51-8C2D08461384224C22F7EE25preparation-assessments-v3.8.json
      /47/legacy_reference/status
      Historical; current review incomplete
      H51-032CF24C1546673FF5E45830preparation-assessments-v3.8.json
      /47/label_resolution/status
      Historical; current review incomplete
      H51-C62A77125C4CAC9C9BC85F6Epreparation-assessments-v3.8.json
      /47/source_files/0
      Historical; current review incomplete
      H51-A8A879C59DA7AB94788F1B37preparation-assessments-v3.8.json
      /47/source_files/1
      Historical; current review incomplete
      H51-678C3AF08AD2B4F8C6A6097Epreparation-assessments-v3.8.json
      /47/source_files/2
      Historical; current review incomplete
      H51-514EE5AF2EC5EE4105F6271Cpreparation-assessments-v3.8.json
      /47/source_files/3
      Historical; current review incomplete
      H51-122D69CE72DD6432746EB94Apreparation-assessments-v3.8.json
      /47/clinical_release_note
      Historical; current review incomplete